Zimmer Biomet Holdings, Inc. (ZBH)
Automate Your Wheel Strategy on ZBH
With Tiblio's Option Bot, you can configure your own wheel strategy including ZBH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZBH
- Rev/Share 40.4392
- Book/Share 71.5422
- PB 1.3245
- Debt/Equity 0.5724
- CurrentRatio 3.2364
- ROIC 0.0472
- MktCap 18779684152.0
- FreeCF/Share 7.1878
- PFCF 13.1889
- PE 23.3134
- Debt/Assets 0.3454
- DivYield 0.0101
- ROE 0.0625
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ZBH | JP Morgan | Overweight | Neutral | -- | $100 | Nov. 6, 2025 |
| Initiation | ZBH | Rothschild & Co Redburn | -- | Buy | -- | $130 | Sept. 18, 2025 |
| Upgrade | ZBH | Roth Capital | Neutral | Buy | -- | $135 | July 15, 2025 |
| Upgrade | ZBH | JP Morgan | Neutral | Overweight | $125 | $128 | Dec. 17, 2024 |
| Initiation | ZBH | Wolfe Research | -- | Peer Perform | -- | -- | Sept. 10, 2024 |
News
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Zimmer Biomet Holdings (ZBH) Faces Investor Scrutiny Amid Emerging Markets Distributor Orders Cancelation, Reduced Top-Line Revenue Forecast -- Hagens Berman
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- On November 5, 2025, investors in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) saw the price of their shares tumble $15.63 (-15%) after the company announced its Q3 2025 financial results and revealed cancelation of emerging markets distributor orders, prompting one analyst to question management's guidance philosophy.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zimmer Biomet Holdings, Inc. - ZBH
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zimmer Biomet Holdings, Inc. ("Zimmer Biomet" or the "Company") (NYSE: ZBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) on behalf of investors concerning the Company's possible violations of federal securities laws.
Read More
Zimmer Biomet Holdings (ZBH) Faces Investor Scrutiny Amid Emerging Markets Distributor Orders Cancelation, Reduced Top-Line Revenue Forecast -- Hagens Berman
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- On November 5, 2025, investors in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) saw the price of their shares tumble $15.63 (-15%) after the company announced its Q3 2025 financial results and revealed cancelation of emerging markets distributor orders, prompting one analyst to question management's guidance philosophy. The developments and significant market reaction have prompted shareholder rights law firm Hagens Berman to open an investigation into whether Zimmer Biomet may have violated the federal securities laws.
Read More
Zimmer Biomet Holdings, Inc. (ZBH) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) investors concerning the Company's possible violations of federal securities laws.
Read More
Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) investors concerning the Company's possible violations of the federal securities laws.
Read More
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Zimmer Biomet Holdings, Inc. ( ZBH ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Ivan Tornos - President, CEO & Chairman of the Board Suketu Upadhyay - CFO and Executive VP of Finance, Operations & Supply Chain Conference Call Participants Matthew Taylor - Jefferies LLC, Research Division Presentation Matthew Taylor Jefferies LLC, Research Division All right. Great. Thanks for joining us for our next session here at the Jefferies Healthcare Conference.
Read More
Zimmer Biomet Holdings (ZBH) Faces Investor Scrutiny Amid Emerging Markets Distributor Orders Cancelation, Reduced Top-Line Revenue Forecast -- Hagens Berman
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- On November 5, 2025, investors in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) saw the price of their shares tumble $15.63 (-15%) after the company announced its Q3 2025 financial results and revealed cancelation of emerging markets distributor orders, prompting one analyst to question management's guidance philosophy.
Read More
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Published: November 13, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZIMMER BIOMET HOLDINGS, INC. (ZBH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happ.
Read More
Time To Buy Zimmer Biomet Stock?
Published: November 06, 2025 by: Forbes
Sentiment: Positive
Zimmer Biomet (ZBH) stock ought to be on your radar. Here's why – it is presently trading within the support range ($83.17 – $91.93), levels from which it has rebounded significantly in the past.
Read More
Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Zimmer Biomet's Q3 EPS beats expectations, but a revenue miss and trimmed outlook send shares sliding in pre-market trading.
Read More
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2025 Earnings Call Transcript
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Zimmer Biomet Holdings, Inc. ( ZBH ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants David DeMartino - Senior Vice President of Investor Relations Ivan Tornos - President, CEO & Chairman of the Board Suketu Upadhyay - CFO and Executive VP of Finance, Operations & Supply Chain Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - BofA Securities, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Patrick Wood - Morgan Stanley, Research Division Larry Biegelsen - Wells Fargo Securities, …
Read More
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
Company to Spotlight Comprehensive Hip & Knee Portfolios and Latest Advancements in Robotics, Including the mBôs™ System Following Recent Acquisition of Monogram Technologies WARSAW, Ind., Oct. 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting bold innovations across its broad robotics and musculoskeletal portfolio at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).
Read More
The Launch of Foot and Ankle Trauma Solutions May Boost ZBH Stock
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer Biomet expands its foot & ankle trauma lineup with Gorilla Pilon Fusion & Phantom TTC Trauma Nail launches.
Read More
Are Investors Undervaluing Zimmer Biomet (ZBH) Right Now?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2025 Financial Results
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
WARSAW, Ind. , Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m.
Read More
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The robotic surgery market is undergoing rapid transformation, driven by technological advancements, increasing adoption in hospitals, and a shift toward minimally invasive procedures. As of 2025, it's growing rapidly, focusing on precision, AI integration, and expanding its use across specialties like urology, gynecology, orthopedics, and general surgery.
Read More
All You Need to Know About Zimmer (ZBH) Rating Upgrade to Buy
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer (ZBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Is Zimmer Biomet (ZBH) Stock Undervalued Right Now?
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
ZBH or ESLOY: Which Is the Better Value Stock Right Now?
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Should You Add Zimmer Biomet Stock to Your Portfolio Now?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.
Read More
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
About Zimmer Biomet Holdings, Inc. (ZBH)
- IPO Date 2001-07-25
- Website https://www.zimmerbiomet.com
- Industry Medical - Devices
- CEO Ivan Tornos
- Employees 17000